Panavance Therapeutics
  • Our Science
    • Pipeline
    • About Misetionamide
    • MOA
  • About
    • About Panavance
    • Leadership
    • Board of Directors
    • Advisors & Collaborators
    • Contact Panavance
  • Resources
    • Publications
    • Brochures
    • Videos
    • Press Releases
    • Events
  • Participate

Let’s engage.

Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian cancer.

August 7, 2024 / 0 Minute Read

panavance therapeutics

  • Our Science
  • About
  • Resources
  • Participate
  • LinkedIn
  • Twitter
  • Facebook

+1.610.922.1910

Copyright © 2024 Panavance Therapeutics Inc.